GlobeNewswire
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
📊
AI Sentiment
Positive
7/10
- Home
- TLSA
as of 12-05-2025 3:44pm EST
$1.73
$0.04
-2.26%
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 200.8M | IPO Year: | 2000 |
| Target Price: | N/A | AVG Volume (30 days): | 243.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $2.60 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered TLSA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 69.80%
69.80%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Tiziana Life Sciences Ltd. News
TLSA Breaking Stock News: Dive into TLSA Ticker-Specific Updates for Smart Investing
Compare TLSA vs Leading Stocks
See how TLSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TLSA Tiziana Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.